Monday, June 20, 2016

BRIEF-GlaxoSmithKline says lung drug meets late-stage study goals

* Fulfil study shows superiority of closed triple

combination therapy ff/umec/vi versus symbicort turbohaler

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)